Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain

Fernández, Óscar; Agüera, Javier; Izquierdo, Guillermo; Millán-Pascual, Javier; Torrentà, Lluís Ramió; Oliva, P. De La; Argente, J; Berdei, Yasmina; Soler, Jose; Carmona, Olga; Errea, José M.; Farrés, Jordi

doi:10.1371/journal.pone.0035600

Cited by 32 publications

(28 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This value was lower than the ones found in studies like a multicenter study conducted in Spain health care centers for MS patients using the Morisky & Green scale, which found an adherence rate of 68% (Fernandez et al, 2012).…”

Section: Discussioncontrasting

confidence: 73%

See 1 more Smart Citation

Factors associated with adherence to immunomodulator treatment in people with multiple sclerosis

Câmara

Gondim

2017

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

To determine the association between factors and adherence to immunomodulator treatment in people with multiple sclerosis treated in reference centers. Cross-sectional study conducted with 188 people who used immunomodulators in three reference centers in Ceará from March to July 2012. Adherence was assessed using the Moriskscale and factors were assessed using a questionnaire addressing socioeconomic and personal characteristics, the disease, the use of immunomodulator and educational activities. The determination of the association was expressed in crude and adjusted odds ratio with a 95% confidence interval. Adherence rate was 46% and after the logistic regression model the adherence to immunomodulator treatment was positively associated with the following factors: age 18-38 years, time of diagnosis and treatment between 6 and 24 months, 0-3.5 score in the Expanded Disability Status Scale, perception of treatment benefits, intrinsic and extrinsic motivation, phone contact with the doctor and not missing the return visit. This study is important because it allowed to determine the association between factors and adherence to immunomodulator treatment in multiple sclerosis, contributing to prevention and control actions.

show abstract

Section: Discussioncontrasting

confidence: 73%

“…It was observed that age (under 39 years old) was statistically significant, corroborating with Fernandez et al (2012). It is believed that the disease progression hinders adherence by older people.…”

Section: Discussionsupporting

confidence: 72%

Factors associated with adherence to immunomodulator treatment in people with multiple sclerosis

Câmara

Gondim

2017

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…Although a relevant proportion of patients discontinue IFNB due to lack of efficacy, an equally relevant proportion does this due to poor tolerability [6,7]. Furthermore, injection-related problems (anxiety, tiredness, injection-site pain or reactions) are other important reasons for non-adherence to IFNB, together with forgetting to administer, even in patients treated for more than 2 years [8,9,10]. A proportion ranging from 23 to 46% of patients treated with immunomodulating injective drugs have been reported as not adherent to IFNB treatment, in terms of both recommended dose and timing [7].…”

Section: Introductionmentioning

confidence: 99%

“…Alternatively, a reduction of administration frequency of sc IFNB-1a or -1b can sometimes be intentionally (to reduce intolerable side effects) or unintentionally (in the case of forgetting to administer) adopted by patients [8,9,10]. However, the long-term consequences on disease activity of reducing administration frequency of sc IFNB are still largely unknown.…”

Section: Introductionmentioning

confidence: 99%

From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study

Prosperini

Mancinelli²,

Pozzilli³

et al. 2014

Eur Neurol

View full text Add to dashboard Cite

Objectives: To investigate whether clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) who required a reduction of administration frequency of interferon-beta (IFNB) were similar to those of patients who did not. Methods: We identified three subgroups of patients under treatment for 24 months with subcutaneous (sc) high-frequency IFNB-1a or -1b: those continuing to receive IFNB according to the drug label (recommended frequency group), those reducing the administration frequency of sc IFNB-1a or -1b (reduced frequency group), and those switched to once weekly intramuscular (im) IFNB (switched group). All patients were followed for further 24 months. The occurrence of relapse, MRI activity and disability worsening were considered as outcome measures. Results: We identified 308 patients, 201 in the recommended frequency group, 70 in the reduced frequency group, and 37 in the switched group. Patients in the reduced frequency group had increased risk for relapses (HR = 1.95, p < 0.001) and MRI activity (HR = 1.41, p < 0.001), while patients in the switched group had increased risk for relapses (HR = 1.67, p = 0.012), but not for MRI activity (HR = 1.26, p = 0.08) than those in the recommended frequency group. Predictors for disease activity re-start after the reduction of IFNB administration frequency were younger age, higher pre-IFNB relapse rate, and reducing sc IFNB frequency to twice weekly rather than switching to im IFNB-1a once weekly. Conclusion: Our findings discourage the reduction of sc IFNB administration frequency, especially in younger patients with a higher pre-IFNB relapse rate. However, switching to im IFNB-1a may be considered in some selected cases.

show abstract

“…To date, there are no other published studies permitting comparison of this data, as most studies have assessed adherence in patients with MS with disease-modifying injection therapies 12 14 26. In a comparative study of fingolimod versus other parenteral therapies in patients with MS, adherence to oral fingolimod was 80–90%, a good approximation as patients’ characteristics might be similar 27.…”

Section: Discussionmentioning

confidence: 99%

Impact of fampridine on quality of life: clinical benefit in real-world practice

et al. 2017

View full text Add to dashboard Cite

ObjectivesTo assess the effectiveness and tolerability of fampridine in patients with multiple sclerosis (MS) in real clinical practice and to analyse adherence to treatment and general satisfaction of patients in terms of quality of life (QOL).MethodsPatients who started treatment with fampridine from May 2014 to October 2014 were included. Primary and secondary outcomes were Timed 25-Foot Walk (T25FW) and MS Walking Scale-12 (MSWS-12) respectively, measured at baseline and 2 weeks, 3 and 6 months. Adherence was measured by the Morisky–Green questionnaire, patient satisfaction with a visual analogue scale (VAS) and QOL with improvement in mobility, self-care, daily activities, pain/discomfort or anxiety/depression.Results30 patients (46.7% women) of mean age 39 years, mean MS duration 13.7 years, mean Expanded Disability Status Scale score 5.8, 57% with relapsing-remitting MS were included. 22 patients (73%) continued to take treatment throughout the study period. Two weeks after treatment initiation all measures improved significantly from baseline (T25FW: −7.5 s, p<0.05; MSWS-12: −36.7, p<0.05). At 6 months, walking speed and self-perceived walking ability were significantly improved (T25FW: −3.8 s, p<0.05; MSWS-12: −30.0, p<0.05). Adverse events were reported by 30% of patients. Seizures were registered in one patient. 70% of patients were adherent with treatment. Median (IQR) general satisfaction VAS score was 8 (7–9). Patients reported an improvement in mobility (70%), anxiety/depression (33.3%), self-care (23.3%), daily activities (23.3%) and pain/discomfort (3.3%).ConclusionsFampridine is effective and safe in patients with MS in real clinical practice up to 6 months. Adherence to treatment was suboptimal but patients' general satisfaction was high and fampridine improved several items of QOL.

show abstract

Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain

Cited by 32 publications

References 31 publications

Factors associated with adherence to immunomodulator treatment in people with multiple sclerosis

Factors associated with adherence to immunomodulator treatment in people with multiple sclerosis

From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study

Impact of fampridine on quality of life: clinical benefit in real-world practice

Contact Info

Product

Resources

About